Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix versus Havrix safety study in women aged 18-25 years
2007-006651-39Phase 4Terminated
- Sponsor
- GSK
- Start
- Jan 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection (2 arms), sponsored by GSK. Primary endpoints: Occurrence of validated autoimmune diseases during the theoretical risk period, Incidence of neuroinflammatory autoimmune diseases or other autoimmune diseases and 1 more. Started Jan 2009; status: terminated.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2007-006651-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006651-39.